Dr. Byung-Ho Rhie | Cancer Awards | Research Excellence Award

Dr. Byung-Ho Rhie | Cancer Awards | Research Excellence Award

Dr. Byung-Ho Rhie | Cancer Awards | Kangwon National University | South Korea

Dr. Byung-Ho Rhie is a highly accomplished biomedical researcher and academic with extensive expertise in cancer biology, stem cell research, and targeted therapeutics, with a particular focus on non-small cell lung cancer (NSCLC) drug resistance mechanisms and human pluripotent stem cell biology. He earned his Ph.D. from the College of Science and Technology, Hanyang University, and has held multiple postdoctoral and senior researcher positions at Hanyang University and Kangwon National University, where he contributed to international collaborative research projects and translational biomedical studies. Dr. Byung-Ho Rhie’s professional experience includes establishing NSCLC research platforms, generating osimertinib-resistant EGFR-mutant cell lines, performing CRISPR/Cas9-mediated knockout of drug resistance factors, and investigating novel therapeutic strategies for drug-resistant cancers. His research on pluripotent stem cells includes developing xeno-free and chemically defined culture conditions, identifying and characterizing deubiquitinating enzymes regulating pluripotency factors such as OCT4 and SOX2, and performing genome-wide CRISPR functional screenings. His scholarly output includes five Scopus-indexed publications with 50 citations and an h-index of 4, demonstrating both depth and impact in biomedical research.

Citation Metrics (Scopus)

60
40
20
0

Citations
50

Documents
5

h-index
4

Citations
Documents
h-index

View Scopus Profile

Featured Publication


EGFR inhibitor suppresses tumor growth by blocking lipid uptake and cholesterol synthesis in non-small cell lung cancer

Rhie, B.-H., et al. (2025). Biochimica et Biophysica Acta – Molecular Basis of Disease.

Dr. Anmin Huang | Immune Oncology | Best Researcher Award

Dr. Anmin Huang | Immune Oncology | Best Researcher Award

Dr. Anmin Huang, Peking university, China

Anmin Huang is a Ph.D. and M.D. candidate in Gastroenterology and Hepatology at Peking University. His research focuses on cancer immunotherapy, immune-related biomarkers, and hepatocellular carcinoma. He has authored several high-impact publications in leading journals such as ACS Applied Materials & Interfaces, Frontiers in Molecular Biosciences, and Hepatobiliary Pancreatic Diseases International, covering topics such as immune and ferroptosis-related signatures, tumor immune infiltration, and multifunctional tumor vaccines. Additionally, he has contributed to multiple patents, including innovations in apoptotic biomimetic nanoparticles for tumor immunotherapy and efficient anti-cancer tumor vaccines. His work integrates computational and experimental approaches to advance cancer treatment strategies, reflecting his expertise in translational medicine and biomedical engineering.

Professional Profile:

ORCID

Summary of Suitability for Best Researcher Award – Anmin Huang

Dr. Anmin Huang, a Ph.D./MD candidate at Peking University specializing in Gastroenterology and Hepatology, has demonstrated exceptional research contributions in the fields of cancer immunotherapy, hepatocellular carcinoma, and tumor microenvironment analysis. His groundbreaking publications, innovative patents, and impactful translational research make him a strong candidate for the Best Researcher Award.

🎓 Education & Work Experience

  • Ph.D./MD Candidate | Peking University, Major: Gastroenterology and Hepatology

  • Researcher | Specializing in immunotherapy, cancer biology, and hepatocellular carcinoma

🏆 Achievements

  • Research Publications 📚

    • Published multiple high-impact papers in ACS Applied Materials & Interfaces, Frontiers in Molecular Biosciences, Hepatobiliary Pancreatic Diseases International, and Engineering

    • Developed immune and ferroptosis-related LncRNA signatures for cancer prognosis

    • Contributed to the study of tumor immune infiltration and immunotherapy response

  • Patents & Innovations 🧪

    • Holder of two utility model patents for laboratory equipment

    • Co-inventor of apoptotic biomimetic nanoparticles for tumor immunotherapy

    • Co-inventor of an anti-cancer tumor vaccine with an innovative preparation method

🎖 Awards & Honors

  • Recognized for cutting-edge research in oncology and immunotherapy

  • Contributions to novel cancer treatment strategies and immune regulation

Publication Top Notes:

Engineered Apoptosis-Bioinspired Nanoparticles Initiate Immune Cascade for Cancer Immunotherapy of Malignant Ascites